Tsimberidou, A. M., Fountzilas, E., Nikanjam, M. & Kurzrock, R. Review of precision cancer medicine: evolution of the treatment paradigm. Cancer Treat. Rev. 86, 102019 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Curigliano, G. et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann. Oncol. 28, 1700–1712 (2017).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kim, E. S. & Pandya, K. J. Advances in personalized therapy for lung cancer. Expert. Opin. Med. Diagn. 7, 475–485 (2013).

Article  CAS  PubMed  Google Scholar 

Duan, L., Mukherjee, E. M. & Narayan, D. Tailoring the treatment of melanoma: implications for personalized medicine. Yale J. Biol. Med. 88, 389–395 (2015).

PubMed  PubMed Central  Google Scholar 

Eggermont, A. M. et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. https://doi.org/10.1016/S1470-2045(15)70122-1 (2015).

Article  PubMed  PubMed Central  Google Scholar 

Eggermont, A. M. et al. Longer follow-up confirms recurrence-free survival benefit of adjuvant pembrolizumab in high-risk stage III melanoma: updated results from the EORTC 1325-MG/KEYNOTE-054 trial. J. Clin. Oncol. 38, 3925–3936 (2020).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hauschild, A. et al. Longer follow-up confirms relapse-free survival benefit with adjuvant dabrafenib plus trametinib in patients with resected BRAF V600-mutant stage III melanoma. J. Clin. Oncol. 36, 3441–3449 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Derks, S. et al. The meaning of screening: detection of brain metastasis in the adjuvant setting for stage III melanoma. ESMO Open 7, 100600 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Patel, S. P. et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N. Engl. J. Med. 388, 813–823 (2023).

Article  CAS  PubMed  Google Scholar 

Ascierto, P. A. et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 21, 1465–1477 (2020).

Article  CAS  PubMed  Google Scholar 

Amaria, R. N. et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 20, e378–e389 (2019).

Article  PubMed  Google Scholar 

Testori, A. A. E., Blankenstein, S. A. & van Akkooi, A. C. J. Surgery for metastatic melanoma: an evolving concept. Curr. Oncol. Rep. 21, 98 (2019).

Article  PubMed  Google Scholar 

van Akkooi, A. C. et al. Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. Eur. J. Surg. Oncol. 33, 102–108 (2007).

Article  PubMed  Google Scholar 

Long, G. V. et al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med. 377, 1813–1823 (2017).

Article  CAS  PubMed  Google Scholar 

Weber, J. S. et al. Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: updated results from a phase III trial (CheckMate 238) [abstract]. J. Clin. Oncol. 36 (Suppl. 15), 9502 (2018).

Article  Google Scholar 

Weber, J. et al. Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. N. Engl. J. Med. 377, 1824–1835 (2017).

Article  CAS  PubMed  Google Scholar 

Bloemendal, M. et al. Early recurrence in completely resected IIIB and IIIC melanoma warrants restaging prior to adjuvant therapy. Ann. Surg. Oncol. 26, 3945–3952 (2019).

Article  PubMed  PubMed Central  Google Scholar 

Matzinger, P. The danger model: a renewed sense of self. Science 296, 301–305 (2002).

Article  CAS  PubMed  Google Scholar 

Versluis, J. M., Long, G. V. & Blank, C. U. Learning from clinical trials of neoadjuvant checkpoint blockade. Nat. Med. 26, 475–484 (2020).

Article  CAS  PubMed  Google Scholar 

Liu, J. et al. Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease. Cancer Discov. 6, 1382–1399 (2016).

Article  CAS  PubMed  Google Scholar 

Blank, C. U. et al. Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. Nat. Med. 24, 1655–1661 (2018).

Article  CAS  PubMed  Google Scholar 

Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948–960 (2019).

Article  CAS  PubMed  Google Scholar 

Rozeman, E. A. et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat. Med. 27, 256–263 (2021).

Article  CAS  PubMed  Google Scholar 

Amaria, R. N. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat. Med. 24, 1649–1654 (2018).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Huang, A. C. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat. Med. 25, 454–461 (2019).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tarhini, A. A. et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS ONE 9, e87705 (2014).

Article  PubMed  PubMed Central  Google Scholar 

Tarhini, A. et al. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J. Immunother. Cancer 6, 112 (2018).

Article  PubMed  PubMed Central  Google Scholar 

Tawbi, H. A. et al. Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma. N. Engl. J. Med. 386, 24–34 (2022).

Article  CAS  PubMed  PubMed Central  Google Scholar 

Long, G. V. et al. NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma [abstract 793P]. Ann. Oncol. 33 (Suppl. 7), S906–S907 (2022).

Article  Google Scholar 

Long, G. V. et al. NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy [abstract]. J. Clin. Oncol. 40 (Suppl. 16), 9503 (2022).

Article  Google Scholar 

Tarhini, A. et al. Neoadjuvant intratumoral TAVO-EP (plasmid IL- 12 electro gene transfer) in combination with nivolumab; preliminary clinical and biomarker data in patients with operable locoregionally advanced melanoma [abstract 617]. J. Immunother. Cancer 10 (Suppl. 2), A649 (2022).

Google Scholar 

Amaria, R. N. et al. Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 19, 181–193 (2018).

Article  CAS  PubMed  Google Scholar 

Long, G. V. et al. Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB-C, BRAFV600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial. Lancet Oncol. 20, 961–971 (2019).

Article  CAS  PubMed  Google Scholar 

Dummer, R. et al. Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial. Nat. Med. 27, 1789–1796 (2021).

Article  CAS  PubMed  Google Scholar 

Menzies, A. M. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat. Med. 27, 301–309 (2021).

Article  CAS  PubMed  Google Scholar 

Lucas, M. W. et al. The NADINA trial: a multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma [abstract]. J. Clin. Oncol. 40 (Suppl. 16), TPS9605 (2022).

Article  Google Scholar 

Topalian, S. L., Taube, J M. & Pardoll, D. M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 367, eaax0182 (2020).

Article  CAS  PubMed  PubMed Central  Goo